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1994; Ward and Dorsa, 1996; Mijnster et al., 1997; Bubser et al., 
2001),   anatomical studies have suggested that cortico-striatal and 
pallidostriatal neurons are the major source of 5-HT2A receptor 
binding in the striatum (Bubser et al., 2001). As such, 5-HT2A-
containing afferents to the striatum offer an anatomical substrate 
for the ability of 5-HT2A receptor antagonists to modulate basal 
ganglia circuitry that may be dysfunctional in PD. Recently, we have 
shown that the 5-HT2A receptor antagonist M100907 but not the 
selective 5-HT2C receptor antagonist SB 206553 improved motor 
impairments in mice treated with 1-methyl-4-phenyl-1,2,3,6-tet-
rahydropyridine (MPTP; Ferguson et al., 2010). A number of stud-
ies in the literature are consistent with the interpretation that the 
5-HT2A receptor regulates glutamatergic transmission in the cortex 
(Aghajanian and Marek, 1997, 1999; Scruggs et al., 2000, 2003). 
Whether 5-HT2A receptor regulates glutamatergic transmission in 
the striatum has not been adequately studied. We hypothesized 
that 5-HT2A receptors localized on cortico-striatal axons regulate 
glutamatergic activity in the striatum and that 5-HT2A receptor 
antagonists may restore motor function by normalizing the overac-
tive glutamatergic drive resulting from DA depletion.
We assessed the effect of the 5-HT2A receptor antagonist M100907 
on motor impairments in MPTP-treated mice. Using in vivo micro-
dialysis, we also determined whether intrastriatal M100907 admin-
istration will alter extracellular glutamate concentrations.
Materials and Methods
aniMals
Male C57BL/6J mice, 70–77 days of age at the start of experiments, 
were obtained from Jackson Labs (Bar Harbor, ME, USA). Animals 
were group housed in a temperature and humidity controlled 
room and maintained on a 12L:12D light–dark cycle (lights off at 
1900 h). Food and water were provided ad libitum. All  studies were 
introduction
Serotonin (5-HT) projections from the dorsal raphe nucleus 
 innervate all components of the basal ganglia circuitry (Lavoie and 
Parent, 1990). 5-HT has been shown to modulate not only dopa-
mine (DA) neurotransmission in the striatum, but also GABA and 
glutamate transmission in the output regions of the basal ganglia 
via a number of 5-HT receptors (Nicholson and Brotchie, 2002). 
Thus, 5-HT may play a regulatory role in voluntary movements of 
the basal ganglia and have a major impact on disorders of the basal 
ganglia such as Parkinson’s disease (PD; Di Matteo et al., 2008). 
Clinical studies have suggested that 5-HT2 receptor antagonists may 
be beneficial in the treatment of the motor symptoms of PD. For 
example, ritanserin, a 5-HT2A/C receptor antagonist, has been shown 
to reduce akinesia and improve gait in PD patients (Henderson 
et al., 1992) as well as ameliorate neuroleptic-induced parkinson-
ism (Bersani et al., 1990). It was reported that ritanserin reduces 
extrapyramidal side effects when added to typical antipsychotics 
(Miller et al., 1990, 1992). Whereas typical antipsychotic drugs 
(APD), which are potent DA D2 antagonists (such as haloperi-
dol), cause parkinsonian side effects, atypical APD with relatively 
high 5-HT2A: DA D2 receptor affinities ratio (such as clozapine) are 
less prone to induce these extrapyramidal parkinsonian-like side 
effects (Altar et al., 1986; Meltzer et al., 1989; Matsubara et al., 1993; 
Nyberg et al., 1993). Furthermore, animal studies have shown that 
haloperidol-induced catalepsy is reduced by 5-HT2A receptor antag-
onists (Balsara et al., 1979; Neal-Beliveau et al., 1993; Bartoszyk 
et al., 1996; Lucas et al., 1997; Young et al., 1999). Lucas et al. (1997) 
showed in rats that the reduction of neuroleptic-induced catalepsy 
by ritanserin was independent of changes in DA dynamics sug-
gesting that the anti-cataleptic effects of ritanserin may involve 
non-dopaminergic targets, possibly glutamatergic. Whereas 5-HT2A 
receptors are widely distributed in the brain (Pompeiano et al., 
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drug treatMents
Mice were injected with 20 mg/kg (ip) MPTP (Sigma-Aldrich, St. 
Louis, MO, USA) or saline every 2 h for a total of four injections, 
resulting in a cumulative dose of 80 mg/kg. All experiments were done 
3 weeks after MPTP administration. The selective 5-HT2A receptor 
antagonist, M100907 [(R-(+)-alpha-(2,3-dimethoxyphenyl)-1-[2-
(4-fluorophenethyl)]-4-piperidinemethanol); Kehne et al., 1996], 
was dissolved in 0.1 M tartaric acid solution and adjusted to pH 
6.5–7.0 with NaOH. All injection volumes were 10 ml/kg. M100903 
was injected intraperitoneally 30 min before behavioral testing. All 
mice received a single dose of either vehicle or M100907. Thus, 
all comparisons were between subjects. The doses of M100907 
(0.0001–0.01 mg/kg) used in the motor function test were based 
on the available literature as well as our previous studies (Ferguson 
et al., 2010) which showed that the selected doses did not alter 
general locomotor behavior.
BeaM-walking apparatus
The apparatus used in this experiment was as described previously 
(Ferguson et al., 2010). It consisted of a 1 cm square stainless steel 
beam of 105 cm in length. The beam was suspended 49 cm above 
the floor of the test chamber. Mice were habituated to the goal box 
for 3 min, then placed a distance of 10 cm from goal box. They were 
allowed to traverse the beam to the goal box. Upon successful traversal 
of the beam to the goal box at the 10 cm distance, mice were placed 
at increasing distances of 30, 50, and 80 cm from the goal box and 
trained to traverse the beam for one trial at each distance for two 
consecutive days. Mice able to traverse the full 80 cm length of the 
beam to the goal box within 60 s were considered to reach criterion. 
Three weeks post-MPTP or saline treatment, mice were subjected 
to three consecutive trials on the beam during which time they were 
videotaped. The number of footslips off the beam in each trial, and 
the mean number of hindlimb footslips during a three-trial session, 
were recorded (Dluzen et al., 2001; Fernagut et al., 2004; Strome et al., 
2006; Allbutt and Henderson 2007; Quinn et al., 2007; Urakawa et al., 
2007) by persons unaware of the treatment condition of the animals. 
A total of 104 mice were trained for studies using the beam-walking 
task. Separate groups of animals were used for assessment of baseline 
beam-walking performance of saline-treated (n = 31), MPTP-treated 
(n = 31) and MPTP-treated mice receiving three doses of M100907 
(n = 14/dose). This approach reduces the possible confound of motor 
learning which can occur with multiple testing of the same animals.
regional MonoaMine concentrations
Separate groups of animals were used to determine the effects of 
MPTP treatment on regional monoamine concentrations. Animals 
(saline, n = 15; MPTP, n = 18) were sacrificed 3 weeks after saline 
or MPTP administration, which is the same time point that the 
behavioral studies and in vivo microdialysis were performed. 
These animals did not receive pharmacological agents. The tissues 
harvested for monoamine determination included the striatum, 
nucleus accumbens, substantia nigra, and cerebellum. The tissues 
were dissected from 1.0 mm thick coronal slices (Deutch et al., 1985) 
and samples stored at −80°C until assayed. Regional concentra-
tions of dopamine and serotonin were determined by HPLC-EC 
as previously described (Deutch and Cameron, 1992), with protein 
concentrations determined by the method of Lowry et al. (1951).
In vIvo Microdialysis
Two weeks after MPTP or saline treatment, mice (saline, n = 11; 
MPTP, n = 11) were implanted with a chronic indwelling guide 
cannula; 5–7 days later the mice were used in dialysis sessions 
examining the ability of the 5-HT2A antagonist M100907 to 
modify glutamate release in the striatum. One day prior to use, 
the efficiency of transmitter recovery by the probe was deter-
mined by collecting three 10-min samples (perfusing flow rate 
of 2.0 μL/min) after placing the probe in a solution of glutamate 
(200 pg/μL) in artificial cerebrospinal fluid (aCSF; 140 mM NaCl, 
3.4 mM KCl, 1.5 mM CaCl2, 1.0 mM MgCl2, 1.4 mM NaH2PO4, 
and 4.85 mM NaHPO4, pH 7.4). Mice were anesthesized with 
isoflurane for stereotaxic surgery to place guide cannula (Plastics 
One; Roanoke, VA, USA) into the right striatum (anterior–pos-
terior, +0.6 mm; dorso-ventral, −4.2 mm; and lateral, 2.0 mm 
relative to bregma; Franklin and Paxinos, 2008). A dual dental 
adhesive (Plastics One; Roanoke, VA, USA) was applied to the 
skull surface and base of the cannula, and then built up with 
a small amount of dental acrylic compound. Four to five days 
post-operatively, the dialysis probe (1.5 mm active exchange sur-
face) was inserted and the animal was placed in a small Plexiglas 
chamber (9′ round) that is placed in the dialysis chamber. The 
swivel assembly and attached tubing was carefully counterbal-
anced to allow free movement of the mouse. The dialysis probe 
was perfused overnight at 0.2 μL/min with aCSF. The following 
morning, the flow rate was increased to 2.0 μL/min. Five 20-min 
baseline samples were collected, after which M100907 (100 nM) 
was administered through the dialysis probe and an additional 
seven fractions were collected. At the end of the experiment mice 
were deeply anesthetized with sodium pentobarbital (60 mg/kg, 
i.p.), perfused intracardially with 4% paraformaldehyde and 
serial coronal sections (40 μm) were cut through the striatum 
and stained with cresyl violet. If the probe placement was not 
correct (i.e., outside the striatum), the data from that animal were 
discarded. The levels of amino acids in the dialysate were deter-
mined using reverse phase HPLC-EC and fluorescent detection. 
Aminobutyric acid was added to dialysis samples as an internal 
standard. Samples were derivatized using o-phthalaldehyde and 
loaded into an autosampler for injection onto a 1.5 micron C18 
column (Alltech Associates; Deerfield, IL, USA). The mobile 
phase was 100 mM sodium phosphate buffer containing 10% 
methanol (pH 3.70) and flow rate was set at 1.2 ml/min with the 
column temperature maintained at 40°C. The glutamate deri-
vatization products were detected with a RF-10Axl fluorescence 
detector (Shimadzu Corp; Kyoto, Japan) and an electrochemical 
detector (ESA; Chelmford, MA, USA) placed in series. Mean 
baseline levels of glutamate were calculated by averaging the 
concentrations of the five basal dialysate samples. If any baseline 
sample from an animal varies by more than 30% of the mean, 
it was eliminated; data from animals with less than three basal 
samples were not included in the analysis.
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not have any effects on the performance of beam-traversal task 
of control mice (Ferguson et al., 2010).
effects of 5-ht2a receptor antagonist M100907 on 
extracellular glutaMate in the striatuM
We hypothesized that 5-HT2A receptor antagonists may restore 
motor function by normalizing the overactive glutamatergic drive 
resulting from DA depletion. We have used in vivo microdialysis to 
determine whether extracellular striatal glutamate is increased in 
mice treated with MPTP and whether local administration of the 
5-HT2A receptor antagonist M100907 will decrease striatal gluta-
mate. The mean basal striatal extracellular glutamate levels in the 
dialysates obtained from saline-treated mice used in these studies 
were 3.41 ± .24 pmol/μL (mean ± SEM; n =  11; Figure 3). Local 
application of 1 μM tetrodotoxin resulted in a dramatic fall in basal 
glutamate output reaching 25% of baseline (data not shown). This 
suggests that a significant fraction of the resting level of striatal 
glutamate is of neuronal origin. Figure 3A depicts the time course 
of the effects of M100907 on basal glutamate levels (expressed 
as percentage of values of saline-injected controls) of saline and 
MPTP-treated mice. MPTP-treated mice exhibited increased basal 
extracellular glutamate levels compared to the saline-treated mice 
(Figure 3A). Local perfusion of 100 nM M100907 into the dorsal 
striatum decreased basal glutamate levels in saline- and MPTP-
treated mice. Two-way ANOVA of the time course data revealed 
significant main effects for treatment [F(1,28) = 230.7; p < 0.0001, 
drug effect, F(1,28) = 305, p < 0.0001, and treatment × drug inter-
action  F(1,28) = 65.67; p  < 0.0001; Figure 3A]. The significant 
treatment x drug interaction suggests that despite elevated basal 
glutamate levels in the MPTP-treated mice, M100907 was capable 
of significantly suppressing glutamate output. Figure 3B com-
pares the effects of M100907 on extracellular glutamate values of 
saline and MPTP-treated mice. The baseline data were obtained 
from the average of five time points and data for drug treatment 
were obtained from average of seven time points from Figure 3A. 
One-way ANOVA revealed significant main effects [F(3,28) = 49.20; 
data analysis
Data were expressed as means ± SEM and analyzed by one-way 
analysis of variance (ANOVA) or two-way ANOVA (microdialy-
sis data). When appropriate, comparisons were carried out with 
Tukey’s post hoc tests. Alpha levels were set at 0.05.
results
regional MonoaMine concentrations
To evaluate the extent of dopaminergic lesion, the levels of DA in the 
striatum, substantia nigra, nucleus accumbens and cerebellum were 
measured by HPLC. MPTP treatment had significant main effect 
on DA in subcortical regions [F(7,107) = 4.542; p < 0.001; Figure 1]. 
Post hoc analysis revealed that DA was significantly decreased in 
the striatum (p < 0.01), substantia nigra and nucleus accumbens 
(p < 0.05) but not in the cerebellum. The 5-HT content in these 
brain regions of MPTP-treated mice remained generally unchanged 
except for a small but insignificant decrease in the substantia nigra 
(data not shown).
effects of 5-ht2a receptor antagonist M100907 on perforMance 
on the BeaM-walking apparatus
1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine produced 
more than 10-fold increase in the number of footslips dur-
ing beam traversal (number of footslips/subject: Control 
0.42 ± 0.12; MPTP 5.97 ± 0.58; n = 31/group). We (Ferguson 
et al., 2010) and others (Fredriksson et al., 1990; Tillerson et al., 
2002; Tillerson and Miller, 2003) have shown that levodopa 
can reverse the MPTP-induced motor deficits suggesting that 
the motor function test employed is sensitive to deficits in 
the nigrostriatal system, believed to underlie motor impair-
ments in PD. There was significant main effect of M100907 
on motor performance of MPTP-treated mice on the beam-
walking apparatus [F(3,76) = 14.183; p < 0.0001; Figure 2]. Post 
hoc analysis showed that M100907 produced dose-dependent 




























Figure 1 | Dopamine concentrations in subcortical regions of saline and 
MPTP-treated mice. Dopamine concentrations were determined 3 weeks 
after the last MPTP injection. In addition to changes in the striatal complex, a 
significant decrease in dopamine in the substantia nigra was seen (n = 10/
group). Abbreviations: CER, cerebellar cortex; NAc, nucleus accumbens; SN, 
substantia nigra; STR, striatum. Data are expressed as percent of saline-
injected control mice. Dopamine concentrations (mean ng/mg protein ± SEM) 
in control mice: STR: 144.7 ± 9.3; NAc: 14.1 ± 0.54; SN: 6.8 ± 0.5; CER: 
0.17 ± 0.05. *p < 0.05, **p < 0.01; relative to saline-injected controls.



























Figure 2 | M100907 relieved motor deficits in MPTP-treated mice. 
MPTP-treated mice received vehicle or various doses of M100907 . Data are 
presented as mean ± SEM. M100907 dose-dependently reduced the number 
of footslips in MPTP-treated mice. *p < 0.05, **p < 0.01; relative to 
saline-injected controls; in one-way ANOVA with Tukey’s post hoc comparison.
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tor antagonist M100907 improved performance of MPTP-treated 
mice on the beam-walking apparatus. In vivo microdialysis studies 
revealed an increase in striatal extracellular glutamate in MPTP-
treated mice and local perfusion of M100907 into the dorsal stria-
tum significantly decreased basal glutamate levels in saline and 
MPTP-treated mice.
Recently, it has been shown that ACP-103 (pimavancerin), a 
potent 5-HT2A receptor inverse agonist that blocks 5-HT agonists 
at 5-HT2A receptors (Vanover et al., 2006) can suppress tacrine-
induced tremulous jaw movements in rats (Vanover et al., 2008). 
Mianserin, a 5-HT2A/C receptor antagonist produced similar anti-
tremor effects in rats (Carlson et al., 2003). These data and our stud-
ies point to the potential beneficial effects of blockade to 5-HT2A 
receptors in motor symptoms of PD.
p < 0.0001; Figure 3B]. Post hoc analysis using the Tukey’s multiple 
comparison test revealed a significant increase (p < 0.001) in basal 
extracellular glutamate values in MPTP-treated mice (Figure 3B). 
Local perfusion of 100 nM M100907 into the dorsal striatum sig-
nificantly decreased basal glutamate levels in saline (p < 0.001) and 
MPTP (p < 0.001)-treated mice (Figure 3B).
discussion
5-HT may play a role in voluntary movements regulated by the 
basal ganglia and have a major impact on disorders of the basal 
ganglia such as PD (Di Matteo et al., 2008). Clinical studies have 
suggested that 5-HT2 receptor antagonists may be useful in the 
treatment of the motor symptoms of PD (Bersani et al., 1990; 
Henderson et al., 1992). We hypothesized that 5-HT2A receptor 
antagonists may restore motor function by regulating glutamater-




































































Figure 3 | M100907 decreased glutamate levels in the dorsal striatum in 
saline and MPTP-treated mice. Data are expressed as percentages of values in 
saline-injected control mice. Dialysis was carried out 3 weeks after MPTP or 
saline treatment and 7 days after the cannula implantation. (A) Five baseline 
samples were first collected and then a challenge dose of M100907 (100 nM) 
and an additional seven samples were collected. (B) The effects of M100907 on 
extracellular glutamate values of saline and MPTP-treated mice. ***p < 0.001 
compared with saline-injected control mice; ###p < 0.001 when compared with 
MPTP-treated mice. The line segment on time course graphs indicate duration 
of drug administration.
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others (Robinson et al., 2003) using in vivo microdialysis   studies 
and   proton magnetic resonance spectroscopy (Chassain et al., 
2008) have demonstrate increased glutamate concentrations in 
the striatum of MPTP-treated mice. Activation of 5-HT2A het-
eroceptors in several brain areas has been shown to evoke gluta-
mate release (Aghajanian and Marek, 1997; Scruggs et al., 2000, 
2003). Thus, it is conceivable that 5-HT2A receptor antagonists may 
restore motor function by normalizing the overactive glutamater-
gic drive resulting from DA depletion. Indeed we have shown that 
local perfusion of M100907 into the dorsal striatum significantly 
decreased basal glutamate levels in MPTP-treated mice. A more 
direct approach will be to demonstrate improvement in motor per-
formance following local application of M100907 into the dorsal 
striatum. These experiments will be the subject of future studies.
In conclusion we have shown that the antiparkinsonian effects 
of 5-HT2A receptor antagonists may be mediated by regulation of 
striatal glutamate and that antagonism of striatal 5-HT2A recep-
tors may offer non-dopaminergic therapeutic target for the motor 
symptoms of PD.
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A possible mechanism of regulation of striatal function by 
5-HT2A receptors comes from studies showing that following 
DA depletion, the hyperactive locomotor behaviors induced by 
intrastriatal infusion of the D1 agonist SKF82958 can be reduced 
by the 5-HT2A receptor antagonist M100907 (Bishop et al., 2005). 
It appears the direct striatal output pathway plays a major role 
in these effects of 5-HT2A receptors (Gresch and Walker, 1999). 
A more plausible mechanism to explain our findings is an indi-
rect action occurring through regulation of glutamate release. 
There are a number of studies that support our hypothesis. For 
example, in situ hybridization and immunohistochemical stud-
ies have revealed widespread distribution of 5-HT2A receptors 
in the striatum (Pompeiano et al., 1994; Ward and Dorsa, 1996; 
Mijnster et al., 1997; Bubser et al., 2001), however the major source 
of 5-HT2A receptors appears to be the heteroceptors located on 
the terminals of the cortico-striatal glutamatergic axons (Bubser 
et al., 2001). It has been postulated that the loss of striatal DA 
removes a tonic inhibitory constraint on cortico-striatal glu-
tamtergic axons (DeLong, 1990). Thus, anatomical studies in the 
6-  hydroxydopamine (6-OHDA)-lesioned rat, MPTP-treated pri-
mates, and PD patients reveal adaptive changes at cortico-striatal 
synapses suggestive of hyperactivity at these glutamatergic syn-
apses (Anglade et al., 1996; Meshul et al., 1999, 2002; Raju et al., 
2008). Consistent with the anatomical studies, we (this study) and 
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